-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, Ddj5NWVm2FNR4VzoDem6UBWGxuoTTi1YZ2Nr1XZ9o+lbELrczB7af1yx+DHqg0q0 oaIPKga0w4yRhP6nYQZiUw== 0000728889-09-000150.txt : 20090127 0000728889-09-000150.hdr.sgml : 20090127 20090126191435 ACCESSION NUMBER: 0000728889-09-000150 CONFORMED SUBMISSION TYPE: SC 13G/A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20090127 DATE AS OF CHANGE: 20090126 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: NEKTAR THERAPEUTICS CENTRAL INDEX KEY: 0000906709 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 943134940 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-45385 FILM NUMBER: 09546436 BUSINESS ADDRESS: STREET 1: 150 INDUSTRIAL RD CITY: SAN CARLOS STATE: CA ZIP: 94070 BUSINESS PHONE: 6506313100 MAIL ADDRESS: STREET 1: 150 INDUSTRIAL ROAD CITY: SAN CARLOS STATE: CA ZIP: 94070 FORMER COMPANY: FORMER CONFORMED NAME: INHALE THERAPEUTIC SYSTEMS INC DATE OF NAME CHANGE: 19980723 FORMER COMPANY: FORMER CONFORMED NAME: INHALE THERAPEUTIC SYSTEMS DATE OF NAME CHANGE: 19940303 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: OPPENHEIMER FUNDS INC CENTRAL INDEX KEY: 0000728889 STANDARD INDUSTRIAL CLASSIFICATION: UNKNOWN SIC - 0000 [0000] IRS NUMBER: 000000000 STATE OF INCORPORATION: CO FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G/A BUSINESS ADDRESS: STREET 1: 6803 SOUTH TUCSON WAY STREET 2: N/A CITY: CENTENNIAL STATE: CO ZIP: 80112-3924 BUSINESS PHONE: 303-768-3200 MAIL ADDRESS: STREET 1: 6803 SOUTH TUCSON WAY STREET 2: N/A CITY: CENTENNIAL STATE: CO ZIP: 80112-3924 FORMER COMPANY: FORMER CONFORMED NAME: OPPENHEIMER MANAGEMENT CORP DATE OF NAME CHANGE: 19940131 SC 13G/A 1 schedule13g.htm AMENDMENT 10 TO SCHEDULE 13G Nektar Therapeutics

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934
(Amendment No. 10)*

Nektar Therapeutics 
(Name of Issuer)

 

Common Stock 

(Title of Class of Securities)

640268108 
(CUSIP Number)

12/31/2008 
(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

[X]

Rule 13d-1(b)

[ ]

Rule 13d-1(c)

[ ]

Rule 13d-1(d)

*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
 
The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).


Page 2 of 4

CUSIP No. 640268108

1.

Names of Reporting Persons:
 
OppenheimerFunds, Inc.

2.

Check the Appropriate Box if a Member of a Group (See Instructions): Joint filing

3.

SEC Use Only

4.

Citizenship or Place of Organization:
Colorado

 

Number of Shares Beneficially Owned by Each Reporting Person With:

5.

Sole Voting Power:

0

6.

Shared Voting Power:

18,944,153

7.

Sole Dispositive Power:

0

8.

Shared Dispositive Power:

18,944,153

9.

Aggregate Amount Beneficially Owned by Each Reporting Person:

18,944,153 (beneficial ownership disclaimed pursuant to Rule 13d-4 of the Exchange Act of 1934)

10.

Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
[ ]

11.

Percent of Class Represented by Amount in Row (9):

20.49%

12.

Type of Reporting Person (See Instructions):
IA


Page 3 of 4

CUSIP No. 640268108

1.

Names of Reporting Persons:
 
Oppenheimer Global Opportunities Fund

2.

Check the Appropriate Box if a Member of a Group (See Instructions): Joint filing

3.

SEC Use Only

4.

Citizenship or Place of Organization:
Colorado

 

Number of Shares Beneficially Owned by Each Reporting Person With:

5.

Sole Voting Power:

0

6.

Shared Voting Power:

18,114,206

7.

Sole Dispositive Power:

0

8.

Shared Dispositive Power:

18,114,206

9.

Aggregate Amount Beneficially Owned by Each Reporting Person:

18,114,206 (beneficial ownership disclaimed pursuant to Rule 13d-4 of the Exchange Act of 1934)

10.

Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
[ ]

11.

Percent of Class Represented by Amount in Row (9):

19.59%

12.

Type of Reporting Person (See Instructions):
IA


Page 4 of 4

Item:

1(a)

Name of Issuer:

Nektar Therapeutics

1(b)

Address of Issuer's Principal Executive Offices:

201 Industrial Road

San Carlos, CA 94070

2(a)

Name of Person Filing:

(a) OppenheimerFunds, Inc.

(b) Oppenheimer Global Opportunities Fund

2(b)

Address of Principal Business Office or, if none, Residence:

(a) Two World Financial Center

225 Liberty Street

New York, NY 10281

(b) 6803 S. Tucson Way
Centennial, CO 80112

2(c)

Citizenship:

(a) Colorado

(b) Massachusetts

2(d)

Title of Class of Securities:
Common Stock

2(e)

CUSIP Number:

640268108

3

OppenheimerFunds, Inc. is an investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E). Oppenheimer Global Opportunities Fund is an investment company registered under section 8 of the Investment Company Act of 1940.

4(a)

Amount beneficially owned:

(i) 18,944,153 (beneficial ownership disclaimed pursuant to Rule 13d-4 of the Exchange Act of 1934) (includes ownership reported in 4(b)(ii) below)

(ii) 18,114,206

4(b)

Percent of class:

(i) 20.49% (includes ownership reported in 4(b)(ii) below)

(ii) 19.59%

4(c)

(i)

 

 

(ii)

 

 

(iii)

 

 

(iv)

Number of shares as to which the person has:

Sole power to vote or to direct the vote:

(a) 0

(b) 0

Shared power to vote or to direct the vote:

(a) 18,944,153
(b) 18,114,206

Sole power to dispose or to direct the disposition of:

(a)      0

(b)     0

Shared power to dispose or to direct the disposition of:

(a) 18,944,153
(b) 18,114,206

5.

Ownership of Five Percent or Less of a Class: [ ]

6.

Ownership of More than Five Percent on Behalf of Another Person.:

N/A

7.

Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company:
N/A

8.

Identification and Classification of Members of the Group:
N/A

9.

Notice of Dissolution of Group:
N/A

10.

Certification:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

01/26/2009

Date

/s/ Mark S. Vandehey

Signature

Mark S. Vandehey, Sr. Vice President

and Chief Compliance Officer

Name/Title

nektar therapeutics a10 13g 123108.rtf

-----END PRIVACY-ENHANCED MESSAGE-----